Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial
- PMID: 25743937
- DOI: 10.1016/S1470-2045(15)70025-2
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial
Abstract
Background: Patients with metastatic castration-resistant prostate cancer have few treatment options. We investigated the safety and efficacy of lenalidomide, an immunomodulatory agent with anti-angiogenic properties, in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
Methods: In this randomised, double-blind, placebo-controlled, phase 3 study, we randomly assigned chemotherapy-naive patients with progressive metastatic castration-resistant prostate cancer in a 1:1 ratio to receive docetaxel (75 mg/m(2)) on day 1 and prednisone (5 mg twice daily) on days 1-21 and either lenalidomide (25 mg) or placebo once daily on days 1-14 of each 21 day treatment cycle. Permuted block randomisation was done with an interactive voice response system and stratified by Eastern Cooperative Oncology Group performance status, geographic region, and type of disease progression. Clinicians, patients, and investigators were masked to treatment allocation. The primary endpoint was overall survival. Efficacy analysis was by intention to treat. Patients who received at least one dose of study drug were included in the safety analyses. This study is registered with ClinicalTrials.gov, number NCT00988208.
Findings: 1059 patients were enrolled and randomly assigned between Nov 11, 2009, and Nov 23, 2011 (533 to the lenalidomide group and 526 to the control group), and 1046 patients received study treatment (525 in the lenalidomide group and 521 in the placebo group). At data cutoff (Jan 13, 2012) after a median follow-up of 8 months (IQR 5-12), 221 patients had died: 129 in the lenalidomide group and 92 in the placebo group. Median overall survival was 17·7 months (95% CI 14·8-18·8) in the lenalidomide group and not reached in the placebo group (hazard ratio [HR] 1·53, 95% CI 1·17-2·00, p=0·0017). The trial was subsequently closed early due to futility. The number of deaths that occurred during treatment or less than 28 days since the last dose were similar in both groups (18 [3%] of 525 patients in the lenalidomide group vs 13 [2%] of 521 patients). 109 (21%) patients in the lenalidomide group and 78 (15%) in the placebo group died more than 28 days from last dose, mainly due to disease progression. At least one grade 3 or higher adverse event was reported in 381 (73%) of 525 patients receiving lenalidomide and 303 (58%) of 521 patients receiving placebo. Grade 3-4 neutropenia (114 [22%] for lenalidomide vs 85 [16%] for placebo), febrile neutropenia (62 [12%] vs 23 [4%]), diarrhoea (37 [7%] vs 12 [2%]), pneumonia (24 [5%] vs five [1%]), dyspnoea (22 [4%] vs nine [2%]), asthenia (27 [5%] vs 17 [3%]), and pulmonary embolism (32 [6%] vs seven [1%]) occurred more frequently in the lenalidomide group than in the placebo group.
Interpretation: Overall survival with the combination of lenalidomide, docetaxel, and prednisone was significantly worse than with docetaxel and prednisone for chemotherapy-naive men with metastatic, castration-resistant prostate cancer. Further research with this treatment combination is not warranted.
Funding: Celgene Corporation.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Comment in
-
The MAINSAIL trial: an expected failure.Lancet Oncol. 2015 Apr;16(4):355-6. doi: 10.1016/S1470-2045(15)70058-6. Epub 2015 Mar 3. Lancet Oncol. 2015. PMID: 25743936 No abstract available.
-
Urological cancer: Is docetaxel the 'black widow' of mCRPC drugs?Nat Rev Clin Oncol. 2015 Jun;12(6):316-8. doi: 10.1038/nrclinonc.2015.79. Epub 2015 Apr 28. Nat Rev Clin Oncol. 2015. PMID: 25917253 No abstract available.
Similar articles
-
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.Lancet Oncol. 2013 Jul;14(8):760-8. doi: 10.1016/S1470-2045(13)70184-0. Epub 2013 Jun 4. Lancet Oncol. 2013. PMID: 23742877 Clinical Trial.
-
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9. Lancet Oncol. 2017. PMID: 29033099 Clinical Trial.
-
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.Lancet Oncol. 2015 Mar;16(3):338-48. doi: 10.1016/S1470-2045(15)70027-6. Epub 2015 Feb 18. Lancet Oncol. 2015. PMID: 25701170 Clinical Trial.
-
Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies.Clin Genitourin Cancer. 2018 Apr;16(2):e277-e287. doi: 10.1016/j.clgc.2017.12.006. Epub 2017 Dec 27. Clin Genitourin Cancer. 2018. PMID: 29352714 Review.
-
Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer.Value Health. 2018 Oct;21(10):1259-1268. doi: 10.1016/j.jval.2018.03.012. Epub 2018 May 4. Value Health. 2018. PMID: 30314628 Review.
Cited by
-
Cost-Effectiveness Analysis for Therapy Sequence in Advanced Cancer: A Microsimulation Approach with Application to Metastatic Prostate Cancer.Med Decis Making. 2023 Oct-Nov;43(7-8):949-960. doi: 10.1177/0272989X231201621. Epub 2023 Oct 9. Med Decis Making. 2023. PMID: 37811793 Free PMC article.
-
Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs.Int J Mol Sci. 2023 Sep 3;24(17):13618. doi: 10.3390/ijms241713618. Int J Mol Sci. 2023. PMID: 37686423 Free PMC article. Review.
-
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.J Clin Oncol. 2023 May 20;41(15):2736-2746. doi: 10.1200/JCO.22.02661. Epub 2023 Apr 11. J Clin Oncol. 2023. PMID: 37040594 Free PMC article.
-
OSCAR: Optimal subset cardinality regression using the L0-pseudonorm with applications to prognostic modelling of prostate cancer.PLoS Comput Biol. 2023 Mar 10;19(3):e1010333. doi: 10.1371/journal.pcbi.1010333. eCollection 2023 Mar. PLoS Comput Biol. 2023. PMID: 36897911 Free PMC article.
-
The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer.Front Oncol. 2023 Jan 16;12:1060864. doi: 10.3389/fonc.2022.1060864. eCollection 2022. Front Oncol. 2023. PMID: 36727071 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical